CXL 1020

Drug Profile

CXL 1020

Alternative Names: CXL-1020

Latest Information Update: 10 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardioxyl Pharmaceuticals; Johns Hopkins University
  • Developer Cardioxyl Pharmaceuticals
  • Class Heart failure therapies; Nitrogen oxides; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute heart failure

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 10 Feb 2015 Discontinued - Phase-II for Acute heart failure (In the elderly, In adults) in USA (IV)
  • 20 Nov 2014 Preclinical pharmacodynamics data in Heart failure presented at the 87th Annual Scientific Sessions of the American Heart Association (AHA-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top